• Create account
  • Log in
Clinical Guidelines
  • Home
  • About
    • About the clinical guidelines
    • Declaring and dealing with competing interests
    • Frequently asked questions
    • Guideline journal articles
  • CCA guidelines
    • Barrett's Oesophagus
    • Bowel cancer
      • Colorectal cancer
      • Surveillance colonoscopy
    • Endometrial cancer
    • Cervical cancer screening
    • Lung cancer
      • Lung cancer prevention & diagnosis
      • Lung cancer treatment
    • Prostate cancer
      • Advanced prostate cancer
      • PSA testing
    • Sarcoma
    • Skin cancer
      • Melanoma
      • Keratinocyte cancer (non-melanoma)
    • Pain management
    • Archive of CCA guidelines
  • COSA guidelines
    • Adolescents and Young Adult (AYA) guidelines
      • AYA early cancer detection
      • AYA psychosocial management
    • Cancer therapy medication safety
    • Gastroenteropancreatic neuroendocrine tumours
    • Head & neck cancer nutrition
    • Teleoncology
  • Hosted
    • Childhood Brain Tumour or Leukaemia
  • National Cancer Prevention Policy
  • View
  • View form
  • Code
  • History
  • Refresh
  • What links here
  • Related changes
  • Special pages
  • Permanent link
  • Page information
  • Browse properties

Citation:Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al 1993

From Cancer Guidelines Wiki
Jump to:navigation, search

Citation


Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993 Apr 2;25(5):805-13 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8478230.



Critical appraisals

  • Assign a critical appraisal


Compare quality appraisals for each clinical question

Cited by

  1. Do unsealed radioisotopes improve survival in metastatic prostate cancer?
  2. What is the effectiveness of unsealed radioisotopes in the management of bone pain from prostate cancer?
  3. What is the evidence that quality of life is improved with unsealed radioisotopes in prostate cancer?
  4. What is the toxicity of unsealed radioisotopes for treatment of metastatic prostate cancer?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Porter_AT,_McEwan_AJ,_Powe_JE,_Reid_R,_McGowan_DG,_Lukka_H,_et_al_1993&oldid=17250"
Cancer Council would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.